Latest Euronext Brussels News



Google faces record EU fine on Tuesday: sources
Yahoo News UK
Brussels accuses Google of giving its own online shopping services top priority in search results to the detriment of other price comparison services. Sources said EU will impose a massive penalty against Google that would break the previous record of ...

06/28/2017 01:44 AM


Genkyotex Initiates Patient Enrollment into Phase 2 Trial of GKT831 ...
Business Wire (press release)
“Alleviating progressive liver injury and fibrosis is an important therapeutic objective in patients with active PBC. We are grateful to the global network of ...

and more »

06/27/2017 05:01 PM


ABLYNX ACHIEVES SECOND MILESTONE IN IMMUNO-ONCOLOGY COLLABORATION WITH MERCK & CO., INC ...
GlobeNewswire (press release)
GHENT, Belgium, 27 June 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that Merck & Co., Inc., Kenilworth, New Jersey, USA, known as MSD outside the United States and Canada, has started an IND-enabling toxicology study with ...

and more »

06/27/2017 06:05 AM


OrthoSpineNews

Bone Therapeutics receives Intent to Grant Notice from European Patent Office for allogeneic bone cell therapy platform
OrthoSpineNews
Gosselies, Belgium, 26 June 2017; 7am CEST – BONE THERAPEUTICS (Euronext Brussels and Paris: BOTHE), the bone cell therapy company addressing high unmet medical needs in orthopaedics and bone diseases, today announces that the European ...

06/27/2017 12:10 AM


Regulated information - Ageas reports on the progress of share buy-back programme
GlobeNewswire (press release)
Further to the initiation of the share buy-back programme announced on 10 August 2016, Ageas reports the purchase of 257,421 Ageas shares on NYSE Euronext Brussels in the period from 19-06-2017 until 23-06-2017.

and more »

06/26/2017 04:41 PM


ABLYNX INITIATES A SINGLE AND MULTIPLE DOSE PHASE I STUDY OF CAPLACIZUMAB IN HEALTHY JAPANESE ...
GlobeNewswire (press release)
GHENT, Belgium, 26 June 2017 - Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced that the first Japanese healthy volunteers have been dosed in the Phase I single centre, randomised, double-blind, placebo-controlled study of caplacizumab, ...

and more »

06/26/2017 06:01 AM